Artificial intelligence (AI)-based drug developer Exscientia has closed on $525 million in financing, with the proceeds intended for advancing its pipeline through clinical trials, as well as expanding its technology platform toward autonomous drug design.
Based in Oxford, U.K., Exscientia has completed a $225 million Series D round led by SoftBank Vision Fund 2 (SVF2). SoftBank also agreed to commit to Exscientia $300 million in equity, from which the company can draw from at its discretion.
